Research ExplorerPublicationsClinical relevance of loss of 11p15 in primary and metastati...

Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.

Standard

Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases. / Wikman, Harriet; Sielaff-Frimpong, Bettina; Kropidlowski, Jolanthe; Witzel, Isabell; Milde-Langosch, Karin; Sauter, Guido; Westphal, Manfred; Lamszus, Katrin; Pantel, Klaus.

In: PLOS ONE, Vol. 7, No. 10, 10, 2012, p. 47537.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wikman, H, Sielaff-Frimpong, B, Kropidlowski, J, Witzel, I, Milde-Langosch, K, Sauter, G, Westphal, M, Lamszus, K & Pantel, K 2012, 'Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.', PLOS ONE, vol. 7, no. 10, 10, pp. 47537. https://doi.org/10.1371/journal.pone.0047537

APA

Wikman, H., Sielaff-Frimpong, B., Kropidlowski, J., Witzel, I., Milde-Langosch, K., Sauter, G., Westphal, M., Lamszus, K., & Pantel, K. (2012). Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases. PLOS ONE, 7(10), 47537. [10]. https://doi.org/10.1371/journal.pone.0047537

Vancouver

Wikman H, Sielaff-Frimpong B, Kropidlowski J, Witzel I, Milde-Langosch K, Sauter G et al. Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases. PLOS ONE. 2012;7(10):47537. 10. https://doi.org/10.1371/journal.pone.0047537

Bibtex

@article{b34fa76adb964d39bbca0c53a9e8e150,
title = "Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.",
abstract = "The occurrence of brain metastases among breast cancer patients is currently rising with approximately 20-25% incidence rates, underlining the importance of the identification of new therapeutic and prognostic markers. We have previously screened for new markers for brain metastasis by array CGH. We found that loss of 11p15 is common among these patients. In this study, we investigated the clinical significance of loss of 11p15 in primary breast cancer (BC) and breast cancer brain metastases (BCBM). 11p15 aberration patterns were assessed by allelic imbalance (AI) analysis in primary BC (n = 78), BCBM (n = 21) and metastases from other distant sites (n = 6) using six different markers. AI at 11p15 was significantly associated with BCBM (p = 0.002). Interestingly, a subgroup of primary BC with a later relapse to the brain had almost equally high AI rates as the BCBM cases. In primary BC, AI was statistically significantly associated with high grade, negative hormone receptor status, and triple-negative (TNBC) tumors. Gene expression profiling identified PRKCDBP in the 11p15 region to be significantly downregulated in both BCBM and primary BC with brain relapse compared to primary tumors without relapse or bone metastasis (fdr",
keywords = "Adult, Humans, Female, Middle Aged, Recurrence, Gene Expression Regulation, Neoplastic, Neoplasm Metastasis, Tumor Markers, Biological/metabolism, Intracellular Signaling Peptides and Proteins/genetics/metabolism, *Brain Neoplasms/pathology/secondary, *Breast Neoplasms/genetics/metabolism/pathology, Chromosomes, Human, Pair 11/genetics, Adult, Humans, Female, Middle Aged, Recurrence, Gene Expression Regulation, Neoplastic, Neoplasm Metastasis, Tumor Markers, Biological/metabolism, Intracellular Signaling Peptides and Proteins/genetics/metabolism, *Brain Neoplasms/pathology/secondary, *Breast Neoplasms/genetics/metabolism/pathology, Chromosomes, Human, Pair 11/genetics",
author = "Harriet Wikman and Bettina Sielaff-Frimpong and Jolanthe Kropidlowski and Isabell Witzel and Karin Milde-Langosch and Guido Sauter and Manfred Westphal and Katrin Lamszus and Klaus Pantel",
year = "2012",
doi = "10.1371/journal.pone.0047537",
language = "English",
volume = "7",
pages = "47537",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

RIS

TY - JOUR

T1 - Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.

AU - Wikman, Harriet

AU - Sielaff-Frimpong, Bettina

AU - Kropidlowski, Jolanthe

AU - Witzel, Isabell

AU - Milde-Langosch, Karin

AU - Sauter, Guido

AU - Westphal, Manfred

AU - Lamszus, Katrin

AU - Pantel, Klaus

PY - 2012

Y1 - 2012

N2 - The occurrence of brain metastases among breast cancer patients is currently rising with approximately 20-25% incidence rates, underlining the importance of the identification of new therapeutic and prognostic markers. We have previously screened for new markers for brain metastasis by array CGH. We found that loss of 11p15 is common among these patients. In this study, we investigated the clinical significance of loss of 11p15 in primary breast cancer (BC) and breast cancer brain metastases (BCBM). 11p15 aberration patterns were assessed by allelic imbalance (AI) analysis in primary BC (n = 78), BCBM (n = 21) and metastases from other distant sites (n = 6) using six different markers. AI at 11p15 was significantly associated with BCBM (p = 0.002). Interestingly, a subgroup of primary BC with a later relapse to the brain had almost equally high AI rates as the BCBM cases. In primary BC, AI was statistically significantly associated with high grade, negative hormone receptor status, and triple-negative (TNBC) tumors. Gene expression profiling identified PRKCDBP in the 11p15 region to be significantly downregulated in both BCBM and primary BC with brain relapse compared to primary tumors without relapse or bone metastasis (fdr

AB - The occurrence of brain metastases among breast cancer patients is currently rising with approximately 20-25% incidence rates, underlining the importance of the identification of new therapeutic and prognostic markers. We have previously screened for new markers for brain metastasis by array CGH. We found that loss of 11p15 is common among these patients. In this study, we investigated the clinical significance of loss of 11p15 in primary breast cancer (BC) and breast cancer brain metastases (BCBM). 11p15 aberration patterns were assessed by allelic imbalance (AI) analysis in primary BC (n = 78), BCBM (n = 21) and metastases from other distant sites (n = 6) using six different markers. AI at 11p15 was significantly associated with BCBM (p = 0.002). Interestingly, a subgroup of primary BC with a later relapse to the brain had almost equally high AI rates as the BCBM cases. In primary BC, AI was statistically significantly associated with high grade, negative hormone receptor status, and triple-negative (TNBC) tumors. Gene expression profiling identified PRKCDBP in the 11p15 region to be significantly downregulated in both BCBM and primary BC with brain relapse compared to primary tumors without relapse or bone metastasis (fdr

KW - Adult

KW - Humans

KW - Female

KW - Middle Aged

KW - Recurrence

KW - Gene Expression Regulation, Neoplastic

KW - Neoplasm Metastasis

KW - Tumor Markers, Biological/metabolism

KW - Intracellular Signaling Peptides and Proteins/genetics/metabolism

KW - Brain Neoplasms/pathology/secondary

KW - Breast Neoplasms/genetics/metabolism/pathology

KW - Chromosomes, Human, Pair 11/genetics

KW - Adult

KW - Humans

KW - Female

KW - Middle Aged

KW - Recurrence

KW - Gene Expression Regulation, Neoplastic

KW - Neoplasm Metastasis

KW - Tumor Markers, Biological/metabolism

KW - Intracellular Signaling Peptides and Proteins/genetics/metabolism

KW - Brain Neoplasms/pathology/secondary

KW - Breast Neoplasms/genetics/metabolism/pathology

KW - Chromosomes, Human, Pair 11/genetics

U2 - 10.1371/journal.pone.0047537

DO - 10.1371/journal.pone.0047537

M3 - SCORING: Journal article

VL - 7

SP - 47537

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 10

M1 - 10

ER -